Molecular structure of AZD5363, CAS Number: 1143532-39-1
AZD5363 (CAS 1143532-39-1)
Alternate Names:
4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide
CAS Number:
1143532-39-1
Molecular Weight:
428.95
Molecular Formula:
C21H25ClN6O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
AZD5363, also referred to as Capivasertib, is a small molecule inhibitor specifically targeting the serine/threonine kinase AKT. This compound exhibits remarkable potency and selectivity against the AKT family of kinases, with a pronounced effect on the AKT1 isoform. By inhibiting AKT activity, AZD5363 hinders the regulation of cell growth, survival, and proliferation. Extensive research has explored AZD5363′s potential as an anti-cancer agent in vitro. Notably, numerous studies have demonstrated its efficacy in reducing tumor growth across various cancer cell lines, including lung, breast, prostate, melanoma, glioblastoma, and ovarian cancer.
AZD5363 (CAS 1143532-39-1) References
- The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. | Li, J., et al. 2013. J Transl Med. 11: 241. PMID: 24088382
- Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. | Toren, P., et al. 2015. Eur Urol. 67: 986-990. PMID: 25151012
- AZD5363 Inhibits Inflammatory Synergy between Interleukin-17 and Insulin/Insulin-Like Growth Factor 1. | Chen, C., et al. 2014. Front Oncol. 4: 343. PMID: 25520943
- AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo. | Ribas, R., et al. 2015. Mol Cancer Ther. 14: 2035-48. PMID: 26116361
- Co-treatment of Salinomycin Sensitizes AZD5363-treated Cancer Cells Through Increased Apoptosis. | Choi, AR., et al. 2015. Anticancer Res. 35: 4741-7. PMID: 26254364
- A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type. | Zhang, Y., et al. 2016. Oncol Lett. 11: 1685-1692. PMID: 26998062
- T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma. | Zhong, S., et al. 2019. Aging (Albany NY). 11: 9043-9059. PMID: 31655798
- Akt Pathway Inhibitors. | Uko, NE., et al. 2020. Curr Top Med Chem. 20: 883-900. PMID: 32091335
- A combination of AZD5363 and FH5363 induces lethal autophagy in transformed hepatocytes. | Patra, T., et al. 2020. Cell Death Dis. 11: 540. PMID: 32681102
- COVID-19 challenges and its therapeutics. | Rehman, SU., et al. 2021. Biomed Pharmacother. 142: 112015. PMID: 34388532
- AKT inhibitor AZD5363 suppresses stemness and promotes anti-cancer activity of 3,3'-diindolylmethane in human breast cancer cells. | Zhu, K., et al. 2021. Toxicol Appl Pharmacol. 429: 115700. PMID: 34464674
- AKT1E17K -mutated meningioma cell lines respond to treatment with the AKT inhibitor AZD5363. | John, P., et al. 2022. Neuropathol Appl Neurobiol. 48: e12780. PMID: 34837233
- Combined treatments with AZD5363, AZD8542, curcumin or resveratrol induce death of human glioblastoma cells by suppressing the PI3K/AKT and SHH signaling pathways. | Mejía-Rodríguez, R., et al. 2023. Biochem Biophys Rep. 33: 101430. PMID: 36714540
- Targeting mitochondrial dynamics by AZD5363 in triple-negative breast cancer MDA-MB-231 cell-derived spheres. | Fu, Y., et al. 2023. Naunyn Schmiedebergs Arch Pharmacol.. PMID: 37093249
Inhibitor of:
ACTR-I, AIDA, Akt, Akt1, Akt3, AP-2β, ARX, BC060267, Bpifa6, BTBD10, BTEB1, BTNL10, Btnl6, Btnl7, C030010C08Rik, C030014O09Rik, C030017K20Rik, C030019I05Rik, C030030A07Rik, C030034I22Rik, C030037F17Rik, C030048H21Rik, C12orf11, C130039O16Rik, C130060K24Rik, C1orf218, C230099D08Rik, C6orf130, CD300LD, CMTM7, DCAMKL3, DIP2C, E47, EG432798, EG436336, EG546325, EG626215, EG626575, Esp4, F8A1, FAM185A, FAM83B, FAM8A1, Fibroblast Growth Factor (FGF), FKHRL1, FLJ40125, GAP-assoc p62, Gm4788, IL-14, ILKAP, LHX2, LRRTM1, MAGE, MAGI-3, NICE-1, Olfr478, Olfr510, Olfr512, Olfr513, Olfr514, Olfr516, Olfr517, Olfr521, Olfr539, Olfr543, Olfr574, Olfr575, Olfr576, Olfr577, Olfr578, Olfr58, Olfr582, Olfr583, Olfr585, Olfr586, Olfr589, Olfr59, Olfr591, Olfr592, Olfr657, Olfr658, Olfr659, OTTMUSG00000012817, Pbx 2, PDAP1, PGs5, PHF14, PIG11, PKB Kinase, PKNβ, PRIC285, Rab L3, RIM-BP3C, SNX31, SRPX2, STRAD, SUR-5, T1R2, TSTD3, UEV3, YadA, Zfp781, ZNF846, and ZSCAN5B.Activator of:
14-3-3 ζ, 1700011H14Rik, ARA70, BC061237, C030046E11Rik, C23, C86695, C87499, C87977, EG546638, EG625424, EG625464, FTS, Gab 2, HIVEP1, hIws1, Ly-6G, PRRG1, and TTK.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AZD5363, 5 mg | sc-503190 | 5 mg | $309.00 |